Despite generating over $100 billion in revenue in 2022, Pfizer’s stock has dropped precipitously. Pfizer’s revenue was relatively flat, hovering between $41 billion and $51 billion, from 2014 to 2020. Then, its mRNA COVID-19 “vaccine” was awarded Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) on December […]